<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00430508</url>
  </required_header>
  <id_info>
    <org_study_id>CS866CM-B-E301</org_study_id>
    <nct_id>NCT00430508</nct_id>
  </id_info>
  <brief_title>Use of the Combination of Olmesartan and Hydrochlorothiazide in Essential Hypertension</brief_title>
  <official_title>Efficacy and Safety of Hydrochlorothiazide (HCTZ) Used as Add-on Therapy in Moderately to Severely Hypertensive Patients Not Adequately Controlled by Olmesartan Medoxomil (OM) 40 mg Monotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daiichi Sankyo, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Daiichi Sankyo Europe, GmbH</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Daiichi Sankyo, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will evaluate the blood pressure lowering effects of two different dosages of the
      combination of olmesartan and hydrochlorothiazide in patients with moderate or severe high
      blood pressure.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2007</start_date>
  <completion_date type="Actual">May 2008</completion_date>
  <primary_completion_date type="Actual">March 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Mean Trough Sitting Diastolic Blood Pressure From Week 8(Baseline) to Week 16</measure>
    <time_frame>8 weeks, change = week 16 - week 8</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Mean Trough Sitting Diastolic Blood Pressure From Week 8(Baseline) to Week 12.</measure>
    <time_frame>4 weeks, change = week 12 - week 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Mean Trough Sitting Systolic Blood Pressure From Week 8(Baseline) to Week 16.</measure>
    <time_frame>8 weeks, change = week 16 - week 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Mean Trough Sitting Systolic Blood Pressure From Week 8(Baseline) to Week 12.</measure>
    <time_frame>4 weeks, change = week 12 - week 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients Achieving Target Blood Pressure at Week 16</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Mean 24-Hour Ambulatory Blood Pressure Monitoring Diastolic Blood Pressure From Week 8(Baseline) to Week 16.</measure>
    <time_frame>8 weeks, change = week 16 - week 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Mean Daytime Ambulatory Blood Pressure Monitoring Diastolic Blood Pressure From Week 8(Baseline) to Week 16.</measure>
    <time_frame>8 weeks, change = week 16 - week 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Mean Night-Time Ambulatory Blood Pressure Monitoring Diastolic Blood Pressure From Week 8(Baseline) to Week 16.</measure>
    <time_frame>8 weeks, change = week 16 - week 8</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">972</enrollment>
  <condition>Essential Hypertension</condition>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>olmesartan medoxomil (OM) /hydrochlorothiazide (HCTZ) Tablet 40mg/0mg + 20mg/12.5mg matching placebo tablet once daily for 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>olmesartan medoxomil (OM) /hydrochlorothiazide (HCTZ) tablets 40mg/25mg + 20mg/12.5mg matching placebo tablet once daily for 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>olmesartan medoxomil (OM)/hydrochlorothiazide (HCTZ) tablets 20mg/12.5mg + 40mg/0mg matching placebo tablet once daily for 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>olmesartan medoxomil (OM)/hydrochlorothiazide (HCTZ) tablets 40mg/12.5mg + 20mg/12.5mg matching placebo tablet once daily for 8 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>olmesartan medoxomil (OM)/hydrochlorothiazide (HCTZ) tablets and placebo</intervention_name>
    <description>olmesartan medoxomil (OM)/hydrochlorothiazide (HCTZ) Tablet 40mg/0mg + 20mg/12.5mg matching placebo tablet once daily for 8 week</description>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>olmesartan medoxomil (OM)/hydrochlorothiazide (HCTZ) tablets</intervention_name>
    <description>olmesartan medoxomil (OM)/hydrochlorothiazide (HCTZ) tablets 40mg/12.5mg + 20mg/12.5mg matching placebo tablet once daily for 8 weeks</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>olmesartan medoxomil/hydrochlorothiazide tablets</intervention_name>
    <description>olmesartan medoxomil (OM)/hydrochlorothiazide (HCTZ) tablets 40mg/25mg + 20mg/12.5mg matching placebo tablet once daily for 8 weeks</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>olmesartan medoxomil/hydrochlorothiazide tablets</intervention_name>
    <description>olmesartan medoxomil (OM)/hydrochlorothiazide (HCTZ) tablets 20mg/12.5mg + 40mg/0mg matching placebo tablet once daily for 8 weeks</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female Europeans aged 18 years or older with moderate to severe hypertension
             (HTN)

        Exclusion Criteria:

          -  Female patients of childbearing potential pregnant, lactating or planning to become
             pregnant during the trial period.

          -  Patients with serious disorders which may limit the ability to evaluate the efficacy
             or safety of the study medication, including cerebrovascular, cardiovascular, renal,
             respiratory, hepatic, gastrointestinal, endocrine or metabolic, haematological or
             oncological, neurological and psychiatric diseases.

          -  Patients having a history of the following within the last six months:

               -  myocardial infarction,

               -  unstable angina pectoris,

               -  percutaneous coronary intervention,

               -  severe heart failure,

               -  hypertensive encephalopathy,

               -  cerebrovascular accident (stroke) or

               -  transient ischaemic attack.

          -  Patients with clinically significant abnormal laboratory values at screening.

          -  Patients with secondary HTN.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Professor Lars Christian Rump, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>University of Ruhr-Bochum</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Pleven</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Beroun</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brno</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chrudim</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hradec Kralove</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jindrichuv Hradec</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kutna Hora</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ostrava</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pardubice</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Plzen</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Prague</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pribram</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Revnice</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sokolov</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Trutnov</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Langres</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pessac</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bochum</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dietzenbach</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Franfurt</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Friedberg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ingelheim</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Karlsbad</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Offenbach</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Siegen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Stuhr-Brinkum</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Elblag</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gdansk</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Inowroclaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Katowice</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Krakow</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Linia</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lodz</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Olawa</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Poznan</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Warszawa</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wroclaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Zamosc</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Girona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Granada</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oviedo</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dnepropetrovsk</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Donetsk</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kharkiv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kiev</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lviv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Odessa</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Uzhgorod</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vinnytsia</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Zaporizhzhya</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Bulgaria</country>
    <country>Czech Republic</country>
    <country>France</country>
    <country>Germany</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>Ukraine</country>
  </location_countries>
  <verification_date>June 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 1, 2007</study_first_submitted>
  <study_first_submitted_qc>February 1, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 2, 2007</study_first_posted>
  <results_first_submitted>February 9, 2009</results_first_submitted>
  <results_first_submitted_qc>April 29, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 17, 2009</results_first_posted>
  <last_update_submitted>June 17, 2009</last_update_submitted>
  <last_update_submitted_qc>June 17, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 25, 2009</last_update_posted>
  <responsible_party>
    <name_title>Bettina Ammentorp</name_title>
    <organization>Daichi Sankyo Europe, GmbH</organization>
  </responsible_party>
  <keyword>Moderate-to-Severe Hypertension</keyword>
  <keyword>Essential Hypertension</keyword>
  <keyword>Combination Therapy</keyword>
  <keyword>Fixed-Combination Dose</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Olmesartan</mesh_term>
    <mesh_term>Hydrochlorothiazide</mesh_term>
    <mesh_term>Olmesartan Medoxomil</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>78 investigative sites screened patients in Europe (19 in Czech Republic, 11 in Germany, 8 in Bulgaria, 5 in Spain, 20 in Ukraine, 1 in France and 14 in Poland).
Sites were either hospitals or general practitioners. First patient in: 17 January 2007 Last patient out: 30 March 2008</recruitment_details>
      <pre_assignment_details>Trial is 2-week taper-off phase and 2 treatment periods. Period I-8-week open-label, OM 40mg. End of Period I, only non-responders randomised to Period II. Blood Pressure controlled patients discontinued. Period II-8-week double-blind four randomized treatment arms. Participant flow is Period II. 972 completed period I, 971 started period II.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>OM/HCTZ 40/25mg + 20/12.5 Matching Placebo</title>
          <description>olmesartan medoxomil/Hydrochlorothizaide 40/25mg tablets, once daily for 8 weeks</description>
        </group>
        <group group_id="P2">
          <title>OM/HCTZ 40/12.5mg + 20/12.5 Matching Placebo</title>
          <description>olmesartan medoxomil/Hydrochlorothizaide 40/12.5mg tablets, once daily for 8 weeks</description>
        </group>
        <group group_id="P3">
          <title>OM/HCTZ 20/12.5mg + 40/0 Matching Placebo</title>
          <description>olmesartan medoxomil/Hydrochlorothizaide 20/12.5mg tablets, once daily for 8 weeks</description>
        </group>
        <group group_id="P4">
          <title>OM/HCTZ 40/0mg + 20/12.5 Matching Placebo</title>
          <description>olmesartan medoxomil/Hydrochlorothizaide 40/0mg tablets, once daily for 8 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="140"/>
                <participants group_id="P2" count="278"/>
                <participants group_id="P3" count="279"/>
                <participants group_id="P4" count="274"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="137"/>
                <participants group_id="P2" count="272"/>
                <participants group_id="P3" count="266"/>
                <participants group_id="P4" count="269"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="13"/>
                <participants group_id="P4" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>responder at visit 4</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>conmed-BP-pulse-ABPM withdrawal criteria</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>not specified</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>OM/HCTZ 40/25mg + 20/12.5 Matching Placebo</title>
          <description>olmesartan medoxomil/Hydrochlorothizaide 40/25mg tablets, once daily for 8 weeks</description>
        </group>
        <group group_id="B2">
          <title>OM/HCTZ 40/12.5mg + 20/12.5 Matching Placebo</title>
          <description>olmesartan medoxomil/Hydrochlorothizaide 40/12.5mg tablets, once daily for 8 weeks</description>
        </group>
        <group group_id="B3">
          <title>OM/HCTZ 20/12.5mg + 40/0 Matching Placebo</title>
          <description>olmesartan medoxomil/Hydrochlorothizaide 20/12.5mg tablets, once daily for 8 weeks</description>
        </group>
        <group group_id="B4">
          <title>OM/HCTZ 40/0mg + 20/12.5 Matching Placebo</title>
          <description>olmesartan medoxomil/Hydrochlorothizaide 40/0mg tablets, once daily for 8 weeks</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="140"/>
            <count group_id="B2" value="278"/>
            <count group_id="B3" value="279"/>
            <count group_id="B4" value="274"/>
            <count group_id="B5" value="971"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="122"/>
                    <measurement group_id="B2" value="240"/>
                    <measurement group_id="B3" value="233"/>
                    <measurement group_id="B4" value="238"/>
                    <measurement group_id="B5" value="833.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="46"/>
                    <measurement group_id="B4" value="36"/>
                    <measurement group_id="B5" value="138.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55.2" spread="8.17"/>
                    <measurement group_id="B2" value="53.7" spread="9.77"/>
                    <measurement group_id="B3" value="55.2" spread="9.47"/>
                    <measurement group_id="B4" value="54.1" spread="8.92"/>
                    <measurement group_id="B5" value="54.5" spread="9.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52"/>
                    <measurement group_id="B2" value="105"/>
                    <measurement group_id="B3" value="100"/>
                    <measurement group_id="B4" value="115"/>
                    <measurement group_id="B5" value="372.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="88"/>
                    <measurement group_id="B2" value="173"/>
                    <measurement group_id="B3" value="179"/>
                    <measurement group_id="B4" value="159"/>
                    <measurement group_id="B5" value="599.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>European</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="140"/>
                    <measurement group_id="B2" value="278"/>
                    <measurement group_id="B3" value="278"/>
                    <measurement group_id="B4" value="274"/>
                    <measurement group_id="B5" value="970.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Mean Trough Sitting Diastolic Blood Pressure From Week 8(Baseline) to Week 16</title>
        <description>Change = Week 16 - Week 8 (baseline).</description>
        <time_frame>8 weeks, change = week 16 - week 8</time_frame>
        <population>Full Analysis Set-Last Observation Carried Forward.</population>
        <group_list>
          <group group_id="O1">
            <title>OM/HCTZ 40/25mg + 20/12.5 Matching Placebo</title>
            <description>olmesartan medoxomil/HCTZ Tablet 40mg/25mg + 20mg/12.5mg matching placebo tablet once daily for 8 weeks</description>
          </group>
          <group group_id="O2">
            <title>OM/HCTZ 40/12.5mg + 20/12.5 Matching Placebo</title>
            <description>olmesartan medoxomil/hydrochlorothiazide tablets 40mg/12.5mg + 20mg/12.5mg matching placebo tablet once daily for 8 weeks</description>
          </group>
          <group group_id="O3">
            <title>OM/HCTZ 20/12.5mg + 40/0 Matching Placebo</title>
            <description>olmesartan medoxomil/hydrochlorothiazide tablets 20mg/12.5mg + 40mg/0mg matching placebo tablet once daily for 8 weeks</description>
          </group>
          <group group_id="O4">
            <title>OM/HCTZ 40/0mg + 20/12.5 Matching Placebo</title>
            <description>olmesartan medoxomil/hydrochlorothiazide tablets 40mg/0mg + 20mg/12.5mg matching placebo tablet once daily for 8 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Mean Trough Sitting Diastolic Blood Pressure From Week 8(Baseline) to Week 16</title>
          <description>Change = Week 16 - Week 8 (baseline).</description>
          <population>Full Analysis Set-Last Observation Carried Forward.</population>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="140"/>
                <count group_id="O2" value="277"/>
                <count group_id="O3" value="279"/>
                <count group_id="O4" value="274"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.16" spread="8.796"/>
                    <measurement group_id="O2" value="-9.13" spread="8.622"/>
                    <measurement group_id="O3" value="-8.10" spread="7.968"/>
                    <measurement group_id="O4" value="-5.66" spread="8.546"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-5.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-6.97</ci_lower_limit>
            <ci_upper_limit>-3.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-3.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-4.79</ci_lower_limit>
            <ci_upper_limit>-2.03</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1788</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-2.32</ci_lower_limit>
            <ci_upper_limit>0.43</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Mean Trough Sitting Diastolic Blood Pressure From Week 8(Baseline) to Week 12.</title>
        <description>Change = Week 12 - Week 8 (baseline).</description>
        <time_frame>4 weeks, change = week 12 - week 8</time_frame>
        <population>Full Analysis Set-Last Observation Carried Forward</population>
        <group_list>
          <group group_id="O1">
            <title>OM/HCTZ 40/25mg + 20/12.5 Matching Placebo</title>
            <description>olmesartan medoxomil/HCTZ Tablet 40mg/25mg + 20mg/12.5mg matching placebo tablet once daily for 8 weeks</description>
          </group>
          <group group_id="O2">
            <title>OM/HCTZ 40/12.5mg + 20/12.5 Matching Placebo</title>
            <description>olmesartan medoxomil/hydrochlorothiazide tablets 40mg/12.5mg + 20mg/12.5mg matching placebo tablet once daily for 8 weeks</description>
          </group>
          <group group_id="O3">
            <title>OM/HCTZ 20/12.5mg + 40/0 Matching Placebo</title>
            <description>olmesartan medoxomil/hydrochlorothiazide tablets 20mg/12.5mg + 40mg/0mg matching placebo tablet once daily for 8 weeks</description>
          </group>
          <group group_id="O4">
            <title>OM/HCTZ 40/0mg + 20/12.5 Matching Placebo</title>
            <description>olmesartan medoxomil/hydrochlorothiazide tablets 40mg/0mg + 20mg/12.5mg matching placebo tablet once daily for 8 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Mean Trough Sitting Diastolic Blood Pressure From Week 8(Baseline) to Week 12.</title>
          <description>Change = Week 12 - Week 8 (baseline).</description>
          <population>Full Analysis Set-Last Observation Carried Forward</population>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="140"/>
                <count group_id="O2" value="277"/>
                <count group_id="O3" value="279"/>
                <count group_id="O4" value="274"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.74" spread="7.879"/>
                    <measurement group_id="O2" value="-7.72" spread="7.606"/>
                    <measurement group_id="O3" value="-6.66" spread="7.090"/>
                    <measurement group_id="O4" value="-4.47" spread="7.197"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-4.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-5.54</ci_lower_limit>
            <ci_upper_limit>-2.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-3.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-4.39</ci_lower_limit>
            <ci_upper_limit>-1.98</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1081</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-1.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-2.19</ci_lower_limit>
            <ci_upper_limit>0.22</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Mean Trough Sitting Systolic Blood Pressure From Week 8(Baseline) to Week 16.</title>
        <description>Change = Week 16 - Week 8 (baseline).</description>
        <time_frame>8 weeks, change = week 16 - week 8</time_frame>
        <population>Full Analysis Set-Last Observation Carried Forward.</population>
        <group_list>
          <group group_id="O1">
            <title>OM/HCTZ 40/25mg + 20/12.5 Matching Placebo</title>
            <description>olmesartan medoxomil/HCTZ Tablet 40mg/25mg + 20mg/12.5mg matching placebo tablet once daily for 8 weeks</description>
          </group>
          <group group_id="O2">
            <title>OM/HCTZ 40/12.5mg + 20/12.5 Matching Placebo</title>
            <description>olmesartan medoxomil/hydrochlorothiazide tablets 40mg/12.5mg + 20mg/12.5mg matching placebo tablet once daily for 8 weeks</description>
          </group>
          <group group_id="O3">
            <title>OM/HCTZ 20/12.5mg + 40/0 Matching Placebo</title>
            <description>olmesartan medoxomil/hydrochlorothiazide tablets 20mg/12.5mg + 40mg/0mg matching placebo tablet once daily for 8 weeks</description>
          </group>
          <group group_id="O4">
            <title>OM/HCTZ 40/0mg + 20/12.5 Matching Placebo</title>
            <description>olmesartan medoxomil/hydrochlorothiazide tablets 40mg/0mg + 20mg/12.5mg matching placebo tablet once daily for 8 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Mean Trough Sitting Systolic Blood Pressure From Week 8(Baseline) to Week 16.</title>
          <description>Change = Week 16 - Week 8 (baseline).</description>
          <population>Full Analysis Set-Last Observation Carried Forward.</population>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="140"/>
                <count group_id="O2" value="277"/>
                <count group_id="O3" value="279"/>
                <count group_id="O4" value="274"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-16.17" spread="13.444"/>
                    <measurement group_id="O2" value="-13.52" spread="14.533"/>
                    <measurement group_id="O3" value="-11.46" spread="13.673"/>
                    <measurement group_id="O4" value="-8.85" spread="13.537"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-7.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-10.13</ci_lower_limit>
            <ci_upper_limit>-4.66</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-5.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-7.4</ci_lower_limit>
            <ci_upper_limit>-2.91</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0255</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-2.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-4.79</ci_lower_limit>
            <ci_upper_limit>-0.31</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Mean Trough Sitting Systolic Blood Pressure From Week 8(Baseline) to Week 12.</title>
        <description>Change = Week 12 - Week 8 (baseline).</description>
        <time_frame>4 weeks, change = week 12 - week 8</time_frame>
        <population>Full Analysis Set-Last Observation Carried Forward</population>
        <group_list>
          <group group_id="O1">
            <title>OM/HCTZ 40/25mg + 20/12.5 Matching Placebo</title>
            <description>olmesartan medoxomil/HCTZ Tablet 40mg/25mg + 20mg/12.5mg matching placebo tablet once daily for 8 weeks</description>
          </group>
          <group group_id="O2">
            <title>OM/HCTZ 40/12.5mg + 20/12.5 Matching Placebo</title>
            <description>olmesartan medoxomil/hydrochlorothiazide tablets 40mg/12.5mg + 20mg/12.5mg matching placebo tablet once daily for 8 weeks</description>
          </group>
          <group group_id="O3">
            <title>OM/HCTZ 20/12.5mg + 40/0 Matching Placebo</title>
            <description>olmesartan medoxomil/hydrochlorothiazide tablets 20mg/12.5mg + 40mg/0mg matching placebo tablet once daily for 8 weeks</description>
          </group>
          <group group_id="O4">
            <title>OM/HCTZ 40/0mg + 20/12.5 Matching Placebo</title>
            <description>olmesartan medoxomil/hydrochlorothiazide tablets 40mg/0mg + 20mg/12.5mg matching placebo tablet once daily for 8 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Mean Trough Sitting Systolic Blood Pressure From Week 8(Baseline) to Week 12.</title>
          <description>Change = Week 12 - Week 8 (baseline).</description>
          <population>Full Analysis Set-Last Observation Carried Forward</population>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="140"/>
                <count group_id="O2" value="277"/>
                <count group_id="O3" value="279"/>
                <count group_id="O4" value="274"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.16" spread="13.337"/>
                    <measurement group_id="O2" value="-10.90" spread="12.297"/>
                    <measurement group_id="O3" value="-9.65" spread="11.743"/>
                    <measurement group_id="O4" value="-6.60" spread="10.932"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-6.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-9.00</ci_lower_limit>
            <ci_upper_limit>-4.26</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-4.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-6.70</ci_lower_limit>
            <ci_upper_limit>-2.81</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0812</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-1.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-3.66</ci_lower_limit>
            <ci_upper_limit>0.21</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients Achieving Target Blood Pressure at Week 16</title>
        <description>Target Blood Pressure is diastolic blood pressure (dBP) &lt; 90 mmHg and systolic blood pressure (sBP) &lt; 140 mmHg for non-diabetics, and dBP &lt; 80 mmHg and sBP &lt; 130 mmHg for diabetics</description>
        <time_frame>8 weeks</time_frame>
        <population>Full Analysis Set-Last Observation Carried Forward</population>
        <group_list>
          <group group_id="O1">
            <title>OM/HCTZ 40/25mg + 20/12.5 Matching Placebo</title>
            <description>olmesartan medoxomil/HCTZ Tablet 40mg/25mg + 20mg/12.5mg matching placebo tablet once daily for 8 weeks</description>
          </group>
          <group group_id="O2">
            <title>OM/HCTZ 40/12.5mg + 20/12.5 Matching Placebo</title>
            <description>olmesartan medoxomil/hydrochlorothiazide tablets 40mg/12.5mg + 20mg/12.5mg matching placebo tablet once daily for 8 weeks</description>
          </group>
          <group group_id="O3">
            <title>OM/HCTZ 20/12.5mg + 40/0 Matching Placebo</title>
            <description>olmesartan medoxomil/hydrochlorothiazide tablets 20mg/12.5mg + 40mg/0mg matching placebo tablet once daily for 8 weeks</description>
          </group>
          <group group_id="O4">
            <title>OM/HCTZ 40/0mg + 20/12.5 Matching Placebo</title>
            <description>olmesartan medoxomil/hydrochlorothiazide tablets 40mg/0mg + 20mg/12.5mg matching placebo tablet once daily for 8 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Achieving Target Blood Pressure at Week 16</title>
          <description>Target Blood Pressure is diastolic blood pressure (dBP) &lt; 90 mmHg and systolic blood pressure (sBP) &lt; 140 mmHg for non-diabetics, and dBP &lt; 80 mmHg and sBP &lt; 130 mmHg for diabetics</description>
          <population>Full Analysis Set-Last Observation Carried Forward</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="140"/>
                <count group_id="O2" value="277"/>
                <count group_id="O3" value="279"/>
                <count group_id="O4" value="274"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59"/>
                    <measurement group_id="O2" value="110"/>
                    <measurement group_id="O3" value="88"/>
                    <measurement group_id="O4" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.67</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.69</ci_lower_limit>
            <ci_upper_limit>4.21</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.20</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.50</ci_lower_limit>
            <ci_upper_limit>3.24</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.55</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.07</ci_lower_limit>
            <ci_upper_limit>2.25</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Mean 24-hour Ambulatory Blood Pressure Monitoring Diastolic Blood Pressure From Week 8(Baseline) to Week 16.</title>
        <description>Change = Week 16 - Week 8 (baseline).</description>
        <time_frame>8 weeks, change = week 16 - week 8</time_frame>
        <population>Full Analysis Set-Observed Cases</population>
        <group_list>
          <group group_id="O1">
            <title>OM/HCTZ 40/25mg + 20/12.5 Matching Placebo</title>
            <description>olmesartan medoxomil/HCTZ Tablet 40mg/25mg + 20mg/12.5mg matching placebo tablet once daily for 8 weeks</description>
          </group>
          <group group_id="O2">
            <title>OM/HCTZ 40/12.5mg + 20/12.5 Matching Placebo</title>
            <description>olmesartan medoxomil/hydrochlorothiazide tablets 40mg/12.5mg + 20mg/12.5mg matching placebo tablet once daily for 8 weeks</description>
          </group>
          <group group_id="O3">
            <title>OM/HCTZ 20/12.5mg + 40/0 Matching Placebo</title>
            <description>olmesartan medoxomil/hydrochlorothiazide tablets 20mg/12.5mg + 40mg/0mg matching placebo tablet once daily for 8 weeks</description>
          </group>
          <group group_id="O4">
            <title>OM/HCTZ 40/0mg + 20/12.5 Matching Placebo</title>
            <description>olmesartan medoxomil/hydrochlorothiazide tablets 40mg/0mg + 20mg/12.5mg matching placebo tablet once daily for 8 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Mean 24-hour Ambulatory Blood Pressure Monitoring Diastolic Blood Pressure From Week 8(Baseline) to Week 16.</title>
          <description>Change = Week 16 - Week 8 (baseline).</description>
          <population>Full Analysis Set-Observed Cases</population>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="120"/>
                <count group_id="O2" value="250"/>
                <count group_id="O3" value="241"/>
                <count group_id="O4" value="249"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.2" spread="7.62"/>
                    <measurement group_id="O2" value="-5.3" spread="8.60"/>
                    <measurement group_id="O3" value="-4.1" spread="9.07"/>
                    <measurement group_id="O4" value="-2.0" spread="7.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-5.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-6.78</ci_lower_limit>
            <ci_upper_limit>-3.36</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-3.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-4.54</ci_lower_limit>
            <ci_upper_limit>-1.78</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1452</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-1.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-2.43</ci_lower_limit>
            <ci_upper_limit>0.36</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Mean Daytime Ambulatory Blood Pressure Monitoring Diastolic Blood Pressure From Week 8(Baseline) to Week 16.</title>
        <description>Change = Week 16 - Week 8 (baseline).</description>
        <time_frame>8 weeks, change = week 16 - week 8</time_frame>
        <population>Full Analysis Set-Observed Cases</population>
        <group_list>
          <group group_id="O1">
            <title>OM/HCTZ 40/25mg + 20/12.5 Matching Placebo</title>
            <description>olmesartan medoxomil/HCTZ Tablet 40mg/25mg + 20mg/12.5mg matching placebo tablet once daily for 8 weeks</description>
          </group>
          <group group_id="O2">
            <title>OM/HCTZ 40/12.5mg + 20/12.5 Matching Placebo</title>
            <description>olmesartan medoxomil/hydrochlorothiazide tablets 40mg/12.5mg + 20mg/12.5mg matching placebo tablet once daily for 8 weeks</description>
          </group>
          <group group_id="O3">
            <title>OM/HCTZ 20/12.5mg + 40/0 Matching Placebo</title>
            <description>olmesartan medoxomil/hydrochlorothiazide tablets 20mg/12.5mg + 40mg/0mg matching placebo tablet once daily for 8 weeks</description>
          </group>
          <group group_id="O4">
            <title>OM/HCTZ 40/0mg + 20/12.5 Matching Placebo</title>
            <description>olmesartan medoxomil/hydrochlorothiazide tablets 40mg/0mg + 20mg/12.5mg matching placebo tablet once daily for 8 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Mean Daytime Ambulatory Blood Pressure Monitoring Diastolic Blood Pressure From Week 8(Baseline) to Week 16.</title>
          <description>Change = Week 16 - Week 8 (baseline).</description>
          <population>Full Analysis Set-Observed Cases</population>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="120"/>
                <count group_id="O2" value="250"/>
                <count group_id="O3" value="241"/>
                <count group_id="O4" value="249"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.0" spread="8.06"/>
                    <measurement group_id="O2" value="-5.5" spread="9.10"/>
                    <measurement group_id="O3" value="-4.0" spread="9.34"/>
                    <measurement group_id="O4" value="-1.8" spread="8.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-5.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-6.79</ci_lower_limit>
            <ci_upper_limit>-3.17</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-3.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-4.79</ci_lower_limit>
            <ci_upper_limit>-1.87</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1629</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-1.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-2.52</ci_lower_limit>
            <ci_upper_limit>0.42</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Mean Night-time Ambulatory Blood Pressure Monitoring Diastolic Blood Pressure From Week 8(Baseline) to Week 16.</title>
        <description>Change = Week 16 - Week 8 (baseline).</description>
        <time_frame>8 weeks, change = week 16 - week 8</time_frame>
        <population>Full Analysis Set-Observed Cases</population>
        <group_list>
          <group group_id="O1">
            <title>OM/HCTZ 40/25mg + 20/12.5 Matching Placebo</title>
            <description>olmesartan medoxomil/HCTZ Tablet 40mg/25mg + 20mg/12.5mg matching placebo tablet once daily for 8 weeks</description>
          </group>
          <group group_id="O2">
            <title>OM/HCTZ 40/12.5mg + 20/12.5 Matching Placebo</title>
            <description>olmesartan medoxomil/hydrochlorothiazide tablets 40mg/12.5mg + 20mg/12.5mg matching placebo tablet once daily for 8 weeks</description>
          </group>
          <group group_id="O3">
            <title>OM/HCTZ 20/12.5mg + 40/0 Matching Placebo</title>
            <description>olmesartan medoxomil/hydrochlorothiazide tablets 20mg/12.5mg + 40mg/0mg matching placebo tablet once daily for 8 weeks</description>
          </group>
          <group group_id="O4">
            <title>OM/HCTZ 40/0mg + 20/12.5 Matching Placebo</title>
            <description>olmesartan medoxomil/hydrochlorothiazide tablets 40mg/0mg + 20mg/12.5mg matching placebo tablet once daily for 8 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Mean Night-time Ambulatory Blood Pressure Monitoring Diastolic Blood Pressure From Week 8(Baseline) to Week 16.</title>
          <description>Change = Week 16 - Week 8 (baseline).</description>
          <population>Full Analysis Set-Observed Cases</population>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="120"/>
                <count group_id="O2" value="250"/>
                <count group_id="O3" value="241"/>
                <count group_id="O4" value="249"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.9" spread="9.51"/>
                    <measurement group_id="O2" value="-4.5" spread="9.90"/>
                    <measurement group_id="O3" value="-4.2" spread="10.61"/>
                    <measurement group_id="O4" value="-2.3" spread="8.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-5.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-7.40</ci_lower_limit>
            <ci_upper_limit>-3.62</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0009</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-2.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-4.12</ci_lower_limit>
            <ci_upper_limit>-1.07</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1985</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-1.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-2.55</ci_lower_limit>
            <ci_upper_limit>0.53</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Results of Study shall not be published without prior express written consent and approval of Sponsor. If Contractor wishes to use data generated at Sites by Investigator, such data includes but not limited to data used in collection of metrics, copy of any intended publication, details of use must be sent in writing to Quintiles and Sponsor for review. Sponsor has right to change proposed publication and/or prohibit publication and Contractor must comply with requirements of Sponsor</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>James McCarthy / Director Regulatory Operations</name_or_title>
      <organization>Daiichi Sankyo</organization>
      <phone>732-590-3430</phone>
      <email>jmccarthy@dsus.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

